Leerink Swann Downgrades Kythera Biopharmaceuticals To Market Perform

Analysts at Leerink Swann downgraded

from Outperform to Market Perform. Kythera Biopharmaceuticals shares have gained 96.46 percent over the past 52 weeks, while the S&P 500 index has surged 7.17 percent in the same period. Kythera Biopharmaceutical's shares rose 0.31 percent to close at $75.38 on Friday.